Dr. James Lederer
Our CSO, Dr. James Lederer, presented at the pre-conference deep dive day on the 26th on the topic ‘Studying the Mechanisms of Action of Polyfunctional Gamma Delta T Cells’. By all reports, it’s an excellent meeting with great ideas circulating and lots to learn.
Synopsis of Dr. Lederer’s presentation:
Dr. Frank Borriello
On Thursday 28th July 2022, Alloplex’s Founder and CEO, Dr. Frank Borriello spoke at the 3rd Gamma Delta T Therapies Summit in a session titled ‘Reviewing the clinical safety and efficacy of gamma delta therapies’ on the Response in Solid Tumors of Non-Engineered Autologous Multi-Cell Therapy.
Synopsis of Dr. Borriello’s presentation:
About the summit:
As newly published data show the first Gamma Delta T cell therapy’s clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun.
The 3rd Gamma Delta T Therapies Summit brought together 120+ of the world’s leaders in the field to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings.
The meeting of with industry pioneers harnessing GDT cells to bring to market more cytotoxic, clinically safe therapies for solid tumor allowed participants to engage in interactive discussions and gain the actionable insights to advance bench to commercial bedside development of γδT-based therapies.